bluuebunny/crossref_metadata_2025_split huggingface dataset:
Exploring app features with outcomes in mHealth studies involving chronic respiratory diseases, diabetes, and hypertension: a targeted exploration of the literature
Authors: Donevant Sara Belle , Estrada Robin Dawson , Culley Joan Marie , Habing Brian , Adams Swann Arp 
Published: July 2018

AbstractObjectivesLimited data are available on the correlation of mHealth features and statistically significant outcomes. We sought to identify and analyze: types and categories of features; frequency and number of features; and relationship of statistically significant outcomes by type, frequency, and number of features.Materials and MethodsThis search included primary articles focused on app-based interventions in managing chronic respiratory diseases, diabetes, and hypertension. The initial search yielded 3622 studies with 70 studies meeting the inclusion criteria. We used thematic analysis to identify 9 features within the studies.ResultsEmploying existing terminology, we classified the 9 features as passive or interactive. Passive features included: 1) one-way communication; 2) mobile diary; 3) Bluetooth technology; and 4) reminders. Interactive features included: 1) interactive prompts; 2) upload of biometric measurements; 3) action treatment plan/personalized health goals; 4) 2-way communication; and 5) clinical decision support system.DiscussionEach feature was included in only one-third of the studies with a mean of 2.6 mHealth features per study. Studies with statistically significant outcomes used a higher combination of passive and interactive features (69%). In contrast, studies without statistically significant outcomes exclusively used a higher frequency of passive features (46%). Inclusion of behavior change features (ie, plan/goals and mobile diary) were correlated with a higher incident of statistically significant outcomes (100%, 77%).ConclusionThis exploration is the first step in identifying how types and categories of features impact outcomes. While the findings are inconclusive due to lack of homogeneity, this provides a foundation for future feature analysis.
The Opioid Epidemic: Moving Toward an Integrated, Holistic Analytical Response
Authors: Morrow Jayne B , Ropero-Miller Jeri D , Catlin Megan L , Winokur Agnes D , Cadwallader Amy B , Staymates Jessica L , Williams Shannan R , McGrath Jonathan G , Logan Barry K , McCormick Michael M , Nolte Kurt B , Gilson Thomas P , Menendez M J , Goldberger Bruce A 
Published: July 2018

AbstractIn many jurisdictions, public safety and public health entities are working together to enhance the timeliness and accuracy of the analytical characterization and toxicology testing of novel synthetic opioids. The improved sharing and early detection of these analytical data are intended to inform surveillance, interdiction efforts, patient intervention and treatment, all of which are critical to curbing the opioid epidemic. Forensic practitioners working to identify novel synthetic opioids struggle to provide timely results when encountering new or unknown substances, such as the fentanyl analogs. These compounds, which mimic heroin in pharmacologic effect but can be far more potent, are inconsistently present in chemical identification libraries, and are currently largely unavailable as reference materials for analytical comparison. Additionally, federal, state and local governments as well as nongovernmental organizations require potency, toxicity and potential-for-abuse data to evaluate the potential health risks of emerging drug threats. Subsequent scheduling efforts and criminal prosecutions also require these thorough drug characterization studies. Pilot programs have demonstrated that early communication of real-time drug toxicity and analytical data significantly impacts the successful response to emerging opioids. High-quality, real-time, national-level data on chemical composition, toxicological test data, drug toxicity and overdoses, and analysis of seized materials by law enforcement are needed to track drug trends. However, the USA still lacks a national system to coordinate and communicate toxicology, medical and medical examiner and coroner data with the broader medical and law enforcement communities. Opportunities to address these gaps as well as recent advancements collected through interagency efforts and technical workshops in the toxicology and analytical chemistry communities are presented here. Opportunities for partnership, increased communication and expanding best practices to move toward an integrated, holistic analytical response are also explored.
‘What cannot often be obtainable’: the Revd Greville John Chester and the Bodleian genizah collection
Authors: Jefferson Rebecca J W 
Published: July 2018

Abstract
The following article examines the Revd Greville John Chester’s activities in the Egyptian antiquities trade from 1889 to 1892, specifically his involvement in discovering and distributing Hebrew manuscripts from the now famous Cairo Genizah. Based on letters written by Chester to the Bodleian Librarian, E.W.B. Nicholson, as well as other supporting documentary evidence, this investigation provides insights into the early history of the Cairo Genizah manuscripts before Solomon Schechter’s celebrated ‘discovery’ of them in 1896/97. Overall, this article shows that the provenance story of ‘the Cairo Genizah’ is multi-faceted and needs to be subjected to much greater scrutiny.
Pseudo-True SDFs in Conditional Asset Pricing Models*
Authors: Antoine Bertille , Proulx Kevin , Renault Eric 
Published: July 2018

Abstract
This article is motivated by the need to bridge some gap between modern asset pricing theory and recent developments in econometric methodology. While asset pricing theory enhances the use of conditional pricing models, econometric inference of conditional models can be challenging due to misspecification or weak identification. To tackle the case of misspecification, we utilize the conditional Hansen and Jagannathan (1997) (HJ) distance as studied by Gagliardini and Ronchetti (2016), but we set the focus on interpretation and estimation of the pseudo-true value defined as the argument of the minimum of this distance. While efficient Generalized Method of Moments (GMM) has no meaning for estimation of a pseudo-true value, the HJ-distance not only delivers a meaningful loss function, but also features an additional advantage for the interpretation and estimation of managed portfolios whose exact pricing characterizes the pseudo-true pricing kernel (stochastic discount factor (SDF)). For conditionally affine pricing kernels, we can display some managed portfolios which are well-defined independently of the pseudo-true value of the parameters, although their exact pricing is achieved by the pseudo-true SDF. For the general case of nonlinear SDFs, we propose a smooth minimum distance (SMD) estimator (Lavergne and Patilea, 2013) that avoids a focus on specific directions as in the case of managed portfolios. Albeit based on kernel smoothing, the SMD approach avoids instabilities and the resulting need of trimming strategies displayed by classical local GMM estimators when the density function of the conditioning variables may take arbitrarily small values. In addition, the fact that SMD may allow fixed bandwidth asymptotics is helpful regarding the curse of dimensionality. In contrast with the true unknown value for a well-specified model, the estimated pseudo-true value, albeit defined in a time-invariant (unconditional) way, may actually depend on the choice of the state variables that define fundamental factors and their scaling weights. Therefore, we may not want to be overly parsimonious about the set of explanatory variables. Finally, following Antoine and Lavergne (2014), we show how SMD can be further robustified to deal with weaker identification contexts. Since SMD can be seen as a local extension of the method of jackknife GMM (Newey and Windmeijer, 2009), we characterize the Gaussian asymptotic distribution of the estimator of the pseudo-true value using classical U-statistic theorems.
Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer
Authors: Lawrence Nicola Jane , Roncolato Felicia , Martin Andrew , Simes Robert John , Stockler Martin R 
Published: July 2018

Abstract

Background
We sought to compare the effect sizes hypothesized in the trial design, observed in the trial results, and considered clinically meaningful by the American Society of Clinical Oncology (ASCO) 2014 recommendations, in phase III trials of targeted and immunological therapies.

Methods
We studied phase III, superiority trials of targeted and immunological therapies in advanced cancers published from 2005 to 2015. We recorded the characteristics, design parameters, and observed results for the primary endpoint of each trial. The effect sizes hypothesized in the trial design were compared with the ASCO 2014 recommendation that phase III trials be designed to detect overall survival (OS) benefits that are clinically meaningful (hazard ratio ≤0.8).

Results
All critical elements of the trial design (effect sizes hypothesized, estimated survival in the control group, power, and significance level) were identified in 165 of 213 included trials (77%). Of trials with a statistically significant result for the primary endpoint, 16 of 30 (53%) with a primary endpoint of OS and 20 of 53 (38%) with a primary endpoint of progression free survival (PFS) had an observed effect size less extreme than hypothesized; and 7 of 30 trials (23%) reported an observed effect size for OS that was statistically significant but not clinically meaningful (HR > 0.80) according to the ASCO 2014 recommendations.

Conclusion
Many trials were designed such that an observed benefit in OS or PFS that was not clinically meaningful would be statistically significant. Phase III trials should be designed to provide results that are statistically significant for observed effects that are clinically meaningful but not for observed results that are of dubious clinical importance.
Prevention and Control of Youth Camp–Associated Acute Gastroenteritis Outbreaks
Authors: Kambhampati Anita K , Marsh Zachary A , Hlavsa Michele C , Roberts Virginia A , Vieira Antonio R , Yoder Jonathan S , Hall Aron J 
Published: July 2018

AbstractBackgroundApproximately 14 million children attend more than 14000 US camps every year. Shared accommodations and activities can facilitate acute gastroenteritis (AGE) outbreaks.MethodsWe analyzed data from the National Outbreak Reporting System on US youth camp–associated AGE outbreaks that occurred between 2009 and 2016. We also conducted a systematic literature search of youth camp–associated AGE outbreaks that have occurred around the world and a gray literature search for existing recommendations on outbreak prevention and control at camps worldwide.ResultsThirty-nine US jurisdictions reported a total of 229 youth camp–associated AGE outbreaks to the National Outbreak Reporting System. Of the 226 outbreaks included in our analyses, 120 (53%) were reported to have resulted from person-to-person transmission, 42 (19%) from an unknown transmission mode, 38 (17%) from foodborne transmission, 19 (8%) from waterborne transmission, 5 (2%) from animal contact, and 2 (<1%) from environmental contamination. Among 170 (75%) outbreaks with a single suspected or confirmed etiology, norovirus (107 [63%] outbreaks), Salmonella spp (16 [9%]), and Shiga-toxin producing Escherichia coli (12 [7%]) were implicated most frequently. We identified 43 additional youth camp–associated AGE outbreaks in the literature that occurred in various countries between 1938 and 2014. Control measures identified through the literature search included camp closure, separation of ill campers, environmental disinfection, and education on food preparation and hand hygiene.ConclusionsYouth camp–associated AGE outbreaks are caused by numerous pathogens every year. These outbreaks are facilitated by factors that include improper food preparation, inadequate cleaning and disinfection, shared accommodations, and contact with animals. Health education focused on proper hygiene and preventing disease transmission could help control or prevent these outbreaks.
The Effects of Sampling Frame Designs on Nonresponse and Coverage Error: Evidence from the Netherlands
Authors: Kölln Ann-Kristin , Ongena Yfke P , Aarts Kees 
Published: July 2018

Abstract
Survey researchers sometimes face several options to formally define and draw random probability samples from their target population of individuals. Relatively little is known about the consequences for the quality of survey estimates when different sampling frames are used, for example frames that list addresses versus individuals While the initial choice for a sampling frame design may be based on diverse criteria, we argue that any decision has consequences for the quality of survey estimates. We hypothesize that knowing respondents’ names upfront decreases nonresponse and coverage error. This can be accomplished by either using person-based sampling frames or augmenting nonperson-based sampling frames with names. We systematically compare sampling frame designs in the context of face-to-face surveys in connection with the European Social Survey (ESS) with the help of three quasi-experimental datasets from a single country. Even the most conservative measures support our hypothesis that the presence of names in the sampling frames could improve response rates, noncontact rates, cooperation rates, and ineligibility rates by between 2.5 and 6 percentage points. Additionally, the accuracy of population estimates could increase. These results suggest that survey researchers collecting individual-level data would be best advised to use well-maintained sampling frame designs (augmented) with person-specific information.
Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis
Authors: Chiang Janet M , Kaysen George A , Segal Mark , Chertow Glenn M , Delgado Cynthia , Johansen Kirsten L 
Published: July 2018

Abstract

Background
Despite the high prevalence of frailty among patients receiving hemodialysis, few preventable or treatable contributing causes have been identified. Hypogonadism is also common in this population and low serum testosterone concentrations share several clinical phenotypes with frailty. We hypothesized that low serum testosterone concentrations would be associated with frailty and several of its individual components.

Methods
We used data from 440 men from A Cohort Study To Investigate the Value of Exercise in ESRD/Analysis Designed to Investigate the Paradox of Obesity and Survival in ESRD, a longitudinal study that recruited participants from 14 dialysis centers in Atlanta, GA and the San Francisco, CA Bay Area from 2009 to 2011. We assessed frailty using the Fried Frailty Phenotype. We examined the association between free testosterone (as a continuous and dichotomous variable) and frailty, individual frailty components, sarcopenia, lower extremity function and muscle mass estimation by creatinine and body impedance spectroscopy over 12 months using generalized estimating equations.

Results
The mean age was 56.1 ± 14.2 years and 27% were white. A 50% lower concentration of free testosterone was associated with 1.40-fold higher odds of being frail [95% confidence interval (CI) 1.05–1.53] and 1.40-fold higher odds of becoming frail over 12 months (95% CI 1.07–1.73). This association was mainly due to an association with two components of frailty: grip strength and gait speed. In addition, 50% lower free testosterone concentration was associated with a 1.55-fold higher odds of having sarcopenia (95% CI 1.09–2.02) and 1.72-fold higher odds for developing sarcopenia (95% CI 1.13–2.33) as well as with lower muscle mass and a decrease in muscle mass over 12 months as estimated by serum creatinine and by bioelectrical impedance spectroscopy.

Conclusion
Serum free testosterone concentration was associated with frailty, physical function, sarcopenia and muscle mass as well as with changes in these outcomes over 12 months. Testosterone replacement may be a feasible therapeutic target toward prevention of frailty, although clinical trials are needed to test this possibility.
The potential of electrocardiography for cardiac risk prediction in chronic and end-stage kidney disease
Authors: Skampardoni Sofia , Poulikakos Dimitrios , Malik Marek , Green Darren , Kalra Philip A 
Published: July 2018

AbstractCardiovascular mortality is very high in chronic and end-stage kidney disease (ESKD). However, risk stratification data are lacking. Sudden cardiac deaths are among the most common cardiovascular causes of death in these populations. As a result, many studies have assessed the prognostic potential of various electrocardiographic parameters in the renal population. Recent data from studies of implantable loop recordings in haemodialysis patients from five different countries have shed light on a pre-eminent bradyarrhythmic risk of mortality. Importantly, heart block addressed by permanent pacing system was detected in a proportion of patients during the prolonged recording periods. Standard electrocardiogram is inexpensive, non-invasive and easily accessible. Hence, risk prediction models using this simple investigation tool could easily translate into clinical practice. We believe that electrocardiographic assessment is currently under-valued in renal populations. For this review, we identified studies from the preceding 10 years that assessed the use of conventional and novel electrocardiographic biomarkers as risk predictors in chronic and ESKD. The review indicates that conventional electrocardiographic markers are not reliable for risk stratification in the renal populations. Novel parameters have shown promising results in smaller studies, but further validation in larger populations is required.
Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease
Authors: Rasmussen Laust Dupont , Bøttcher Morten , Ivarsen Per , Jørgensen Hanne Skou , Nyegaard Mette , Buttenschøn Henriette , Gustafsen Camilla , Glerup Simon , Bøtker Hans Erik , Svensson My , Winther Simon 
Published: July 2018

Abstract

Background
Chronic kidney disease is a risk factor for premature development of coronary atherosclerosis and mortality. A high level of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a recently recognized cardiovascular risk factor and has become the target of effective inhibitory treatment. In 167 kidney transplantation candidates, we aimed to: (i) compare levels of PCSK9 with those of healthy controls, (ii) examine the association between levels of PCSK9 and low-density lipoprotein cholesterol (LDL-c) and the degree of coronary artery disease (CAD) and (iii) evaluate if levels of PCSK9 predict major adverse cardiac events (MACE) and mortality.

Methods
Kidney transplant candidates (n = 167) underwent coronary computed tomography angiography (CCTA) and invasive coronary angiography (ICA) before transplantation. MACE and mortality data were extracted from the Western Denmark Heart Registry, a review of patient records and patient interviews. A group of 79 healthy subjects were used as controls.

Results
Mean PCSK9 levels did not differ between healthy controls and kidney transplant candidates. In patients not receiving lipid-lowering therapy, PCSK9 correlated positively with LDL-c (rho = 0.24, P &lt; 0.05). Mean PCSK9 was similar in patients with and without obstructive CAD at both CCTA and ICA. In a multiple regression analysis, PCSK9 was associated with neither LDL-c (β=−6.45, P = 0.44) nor coronary artery calcium score (β=2.17, P = 0.84). During a follow-up of 3.7 years, PCSK9 levels were not associated with either MACE or mortality.

Conclusions
The ability of PCSK9 levels to predict cardiovascular disease and prognosis does not seem to apply to a cohort of kidney transplant candidates.
The relationship between urinary albumin excretion, cardiovascular outcomes and total mortality among a large cohort of insulin-treated patients with type 2 diabetes in routine primary care practices
Authors: Anyanwagu Uchenna , Donnelly Richard , Idris Iskandar 
Published: July 2018

Abstract

Background
Albuminuria is a recognized diagnostic and prognostic marker of chronic kidney disease and cardiovascular (CV) risk but the well-known relationship between increments in urinary albumin:creatinine ratio (UACR) and CV outcomes and mortality has not been fully explored in insulin-treated patients with type 2 diabetes (T2D) in routine clinical care.

Methods
We investigated data for insulin users with T2D from UK general practices between 2007 and 2014. The UACR at the time of insulin initiation was measured and categorized as &lt;10, 10– 29, 30–300 and &gt;300 mg/g. Patients were followed up for 5 years or the earliest occurrence of all-cause mortality, non-fatal myocardial infarction or stroke. Cox proportional hazards models were fitted to estimate the risk of a composite of these events.

Results
A total of 12 725 patients with T2D (mean age 58.6 ± 13.8 years, mean haemoglobin A1c 8.7 ± 1.8%) initiating insulin therapy between 2007 and 2014 met the inclusion criteria. Compared with patients whose ACR levels at insulin initiation were &lt;10 mg/g, the adjusted risk of the 3-point composite endpoint was 9, 30 and 98% higher in those with ACR levels between 10–29, 30–300 and &gt;300 mg/g, respectively, after a follow-up period of 5 years. The ACR category on its own did not predict risk of all-cause mortality.

Conclusions
This study shows that in patients with T2D on insulin therapy, increased urinary ACR is independently associated with an increased risk of major adverse CV events and all-cause mortality.
Modern Surgical Management of Early Onset and Adolescent Idiopathic Scoliosis
Authors: Beauchamp Eduardo C , Anderson Richard C E , Vitale Michael G 
Published: July 2018

Abstract
The early principles of spinal fusion in the adolescent population focused on preventing progression while simultaneously correcting the spinal deformity. These principles have remained relatively unchanged since their introduction more than a century ago, but recent improvements in imaging, instrumentation, and corrective techniques have provided new insight on the diagnosis, management, and postoperative care of this condition. Treatment options for the management of patients with early onset scoliosis have also evolved dramatically over the last 2 decades. Further knowledge on the physiology of lung development and the detrimental effects of early fusion in the early onset scoliosis population has led to the development of growth friendly implants and other surgical techniques that allow correction of the deformity while maintaining spine, lung, and chest wall development. The following is an overview of current techniques on the management of adolescent idiopathic and early onset scoliosis to help provide guidance on the available surgical alternatives to address these conditions.